Identity
- Security key
- 12059
- Ticker
- AUPH
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2009-10-21
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- AUPH
Detail
Enriched 2026-08-14 20:47
- Market cap
- $2,055,640,545.6
- Shares outstanding (class)
- 133,051,168
- Shares outstanding (weighted)
- 133,051,168
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 128
- Location
- EDMONTON, A0
- Homepage
- https://www.auriniapharma.com
- Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.